25 results
8-K
EX-99.1
HUMA
Humacyte Inc
22 Mar 24
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
7:06am
acceptance of our filing in February 2024 brings us another major step closer to our goal of providing an innovative regenerative medicine product
8-K
EX-99.1
HUMA
Humacyte Inc
9 Feb 24
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
8:06am
of Humacyte. “The BLA acceptance brings us a major step closer to our goal of providing an innovative regenerative medicine product for patients suffering
8-K
EX-99.1
HUMA
Humacyte Inc
26 Jul 23
Humacyte Completes Enrollment in Phase 2/3 Trial of
8:07am
to support a BLA filing for Humacyte’s HAV in vascular trauma repair. The HAV, an innovative regenerative medicine product candidate, is designed
DEF 14A
z01houp xiqqls1xf
29 Apr 22
Definitive proxy
6:41am
424B7
tm37 gytjlc
4 Apr 22
Prospectus with selling stockholder info
5:22pm
POS AM
59gy8vett4o7zy7 lwd
30 Mar 22
Prospectus update (post-effective amendment)
5:07pm
8-K
EX-99.1
lrh45bw18w
29 Mar 22
Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update
7:04am
424B7
ou7574
10 Dec 21
Prospectus with selling stockholder info
12:00am
POS AM
xd1d kjb601ukhwv9m6
19 Nov 21
Prospectus update (post-effective amendment)
5:26pm
424B7
5hxqusqafrj
27 Oct 21
Prospectus with selling stockholder info
2:42pm
8-K
EX-99.3
0kcdpk2ou
27 Aug 21
Report of Independent Registered Public Accounting Firm
9:01pm
8-K
EX-99.2
kao6e im0rn6
26 May 21
Regulation FD Disclosure
4:03pm
425
EX-99.2
0eb2mtf
26 May 21
Business combination disclosure
4:01pm
8-K
EX-99.1
y4p o92tk
14 Apr 21
Humacyte Secures $50 Million Debt Facility with Silicon Valley Bank
4:08pm